

# Juan Francisco SÃ¡nchez MuÃ±oz Torre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7207630/publications.pdf>

Version: 2024-02-01

27  
papers

861  
citations

686830

13  
h-index

552369

26  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1243  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained low-density lipoprotein cholesterol <math>\leq 70\text{ mg/dl}</math> is associated with improved cardiovascular outcomes in the clinical setting. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13732.	1.7	3
2	Location of recurrent cardiovascular events and anticardiolipin antibodies. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13533.	1.7	3
3	Validation of the QMon-20 oscillometric blood pressure monitor for professional office use in the general population according to the ANSI/ESH/ISO 81060-2:2018 protocol. <i>Blood Pressure Monitoring</i> , 2021, 26, 393-395.	0.4	0
4	Systolic Blood Pressure and Outcomes in Stable Outpatients with Recent Symptomatic Artery Disease: A Population-Based Longitudinal Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9348.	1.2	6
5	Metabolic Syndrome and Its Components in Patients with COVID-19: Severe Acute Respiratory Syndrome (SARS) and Mortality. A Systematic Review and Meta-Analysis. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 162.	0.8	9
6	Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease. <i>Atherosclerosis</i> , 2020, 292, 84-89.	0.4	6
7	Cardio-ankle vascular index (CAVI) measured by a new device: protocol for a validation study. <i>BMJ Open</i> , 2020, 10, e038581.	0.8	6
8	Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2020, 73, 828-834.	0.4	3
9	Effectiveness of body roundness index in predicting metabolic syndrome: A systematic review and meta-analysis. <i>Obesity Reviews</i> , 2020, 21, e13023.	3.1	65
10	Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 989-996.	0.6	29
11	Multivariate analysis for coronary heart disease in heterozygote familial hypercholesterolemia patients. <i>Personalized Medicine</i> , 2018, 15, 87-92.	0.8	4
12	Raised Fibrinogen Levels and Outcome in Outpatients With Peripheral Artery Disease. <i>Angiology</i> , 2018, 69, 507-512.	0.8	19
13	Automatic or manual arterial path for the ankle-brachial differences pulse wave velocity. <i>PLoS ONE</i> , 2018, 13, e0206434.	1.1	5
14	Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease. <i>Atherosclerosis</i> , 2018, 276, 10-14.	0.4	33
15	Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism. <i>TH Open</i> , 2018, 02, e210-e217.	0.7	7
16	Predicting Cardiovascular Events in Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 135, 2133-2144.	1.6	270
17	Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1278-1285.	1.2	221
18	Anemia and Outcome in Outpatients With Peripheral Artery Disease. <i>Angiology</i> , 2016, 67, 484-489.	0.8	14

#	ARTICLE	IF	CITATIONS
19	Supervised versus non-supervised exercise in patients with recent myocardial infarction: A propensity analysis. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 245-252.	0.8	8
20	Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study. <i>International Journal of Cardiology</i> , 2015, 201, 79-84.	0.8	32
21	rs1801275 Interleukin-4 receptor alpha polymorphism in familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2014, 8, 418-422.	0.6	2
22	Influence of recent immobilization or surgery on mortality in cancer patients with venous thromboembolism. <i>Thrombosis Research</i> , 2014, 133, S29-S34.	0.8	7
23	Cilostazol and outcome in outpatients with peripheral artery disease. <i>Thrombosis Research</i> , 2014, 134, 331-335.	0.8	13
24	Renal function and short-term outcome in stable outpatients with coronary, cerebrovascular or peripheral artery disease. <i>Atherosclerosis</i> , 2013, 229, 258-262.	0.4	16
25	Alcohol consumption and outcome in stable outpatients with peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2011, 54, 1081-1087.	0.6	20
26	Concomitant Use of Proton Pump Inhibitors and Clopidogrel in Patients With Coronary, Cerebrovascular, or Peripheral Artery Disease in the Factores de Riesgo y Enfermedad Arterial (FRENA) Registry. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 57, 13-19.	0.8	25
27	Body mass index and outcome in patients with coronary, cerebrovascular, or peripheral artery disease: findings from the FRENA registry. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 457-463.	3.1	35